bioRxivBioinformaticsPreprint
INAEME: Integral Neoantigen Analysis with Entirety of Mutational Events
Vladimir KovačevićiD, Ognjen S. MiliceviciD, Nevena Ilic Raicevic, Milica Kojicic, Ana Mijalkovic Lazic, Nikola Skundric, Jack DiGiovannaiD
Abstract
Neoantigens are peptides presented on the surface of cancer cells that can be recognized by the immune system. Multiple novel therapeutic approaches involve the administration of neoantigens to trigger immunity-induced tumor regression. Identifying neoantigens includes a personalized approach consisting of detailed analyses of the sequenced tumor tissue and its comparison with wild type to identify somatic mutations. Altered peptides are translated from nucleotides around somatic mutations, and their binding affinity and immunogenicity need further evaluation. Still, the entire bioinformatics analysis is very complex, and accurate prediction of the neoantigen candidates represents a true challenge. Here, we present the novel, integral bioinformatic analysis workflow for neoantigen discovery, denoted INAEME (Integral Neoantigen Analysis with Entirety of Mutational Events). The workflow performs integral processing of an individuals DNA tumor-normal and RNA tumor raw reads to output prioritized neoantigen candidates. Through conducted analysis and benchmarks, our main goal was to demonstrate the necessity of taking into account a wide scope of mutational events so far not considered in the existing solutions, including phasing of variants, influence of both somatic and germline variants, positions of all transcripts, neighboring variants, and frameshifts. The influence of each mutational event on the accuracy of predicted neoepitope candidates is tested across 300 TCGA samples from multiple cancer types, including melanoma, hepatocellular carcinoma, and lung squamous cancer. The observed loss of neoantigen nests, going from 8.45% up to 23.65%, underscores the importance of accounting for the entirety of mutational events to accurately identify robust neoantigen candidates for cancer immunotherapy and vaccine development. The adaptation of the described methods in the bioinformatics analysis minimizes the existence of false positives, which are only later discovered in a laboratory environment using expensive methods such as mass spectrometry or microscopy.
- organism: human
- assay: whole-exome sequencing
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: variant calling
- research focus: gene regulatory network inference
- approach: statistical model
- approach: benchmark study
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- neoANT-HILL: an integrated tool for identification of potential neoantigens
Ana Carolina Coelho, André Fonseca, … SANDRO JOSÉ DE SOUZA·BMC Medical GenomicsPeer-reviewed·Feb 22, 2020
- A multifunctional R package for identification of tumor-specific neoantigens
Takanori Hasegawa, Shuto Hayashi, … Seiya Imoto·bioRxiv·Dec 9, 2019
- LENS - Landscape of Effective Neoantigens Software
S. P. Vensko, K. Olsen, … B. Vincent·bioRxiv·Apr 1, 2022
- ProGeo-neo: a Customized Proteogenomic Workflow for Neoantigen Prediction and Selection
Yuyu Li, Guangzhi Wang, … Lu Xie·BMC Medical GenomicsPeer-reviewed·Apr 1, 2020
- Proteogenomic analysis reveals RNA as an important source for tumor-agnostic neoantigen identification correlating with T-cell infiltration
C. Tretter, N. de Andrade Kraetzig, … A. M. Krackhardt·bioRxiv·Sep 17, 2022
- Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy